10-Q: RF Acquisition Corp II Extends Business Combination Deadline Amidst Going Concern Doubts

RF Acquisition Corp II's Q3 2026 filing reveals continued efforts to secure a business combination, but highlights substantial doubt regarding its ability to continue as a going concern.

Summary

• RF Acquisition Corp II (RFAIU) filed its quarterly report for the period ending September 30, 2026.
• The company is a blank check company focused on a business combination, primarily targeting deep technology sectors in Asia.
• As of September 30, 2026, the company had $29,601 in cash and a working capital deficit of $1,819,868.
• Substantial doubt exists about the company's ability to continue as a going concern within one year due to its lack of operations, ongoing pursuit of a business combination, and potential need for additional financing.
• The company has extended its deadline to complete a business combination multiple times, with the current target date being November 15, 2026, subject to further extensions.
• A business combination agreement with Nanyang Biologics Pte. Ltd. (Nanyang) was entered into on October 2, 2025, and approved by shareholders on August 19, 2026, but remains subject to closing conditions.
• Significant redemptions by shareholders have occurred, reducing the amount in the trust account.
• The company reported a net loss of $103,394 for the three months ended September 30, 2026, and a net income of $94,735 for the nine months ended September 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the substantial doubt about the company's ability to continue as a going concern and the ongoing delays in consummating a business combination.

Positives

• Shareholder approval for the business combination with Nanyang Biologics Pte. Ltd. was obtained on August 19, 2026.
• The company has secured multiple extensions to its business combination deadline, currently set for November 15, 2026, indicating continued efforts to find a suitable target.
• Interest earned on the trust account provided $1,346,954 in income for the nine months ended September 30, 2026.
• The Sponsor and management team have the option, but not the obligation, to provide additional loans for working capital.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern within one year.
• The company has a working capital deficit of $1,819,868 as of September 30, 2026.
• Significant shareholder redemptions have occurred, reducing the trust account balance.
• The company has incurred net losses in the most recent reported quarter ($103,394 for Q3 2026).
• The business combination with Nanyang is still subject to closing conditions.
• The company has not generated any operating revenues and has no current operations.

Risks

• The company may not be able to complete a business combination within the extended Combination Period, leading to liquidation.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may not be able to obtain additional financing to complete its business combination or if a significant number of public shares are redeemed.
• Geopolitical instability, including the Russia-Ukraine conflict and the Israel-Hamas conflict, could adversely affect the company's search for a business combination.
• The company's disclosure controls and procedures were not effective due to material weaknesses in internal controls, including inadequate segregation of duties and insufficient written policies.
• The consummation of the Business Combination with Nanyang is subject to the satisfaction or waiver of applicable closing conditions.

Future Outlook

The company's primary focus remains on completing its business combination with Nanyang Biologics Pte. Ltd. The deadline for this has been extended to November 15, 2026. However, substantial doubt exists about the company's ability to continue as a going concern, and it may require additional financing or face liquidation if the business combination is not completed.

Management Comments

• Management has determined that conditions raise substantial doubt about the company's ability to continue as a going concern within one year after the date that the unaudited financial statements are issued.
• The company may need to obtain additional financing either to complete its Business Combination or because the Company becomes obligated to redeem a significant number of its public shares upon completion of the Business Combination.
• Disclosure controls and procedures were not effective due to the material weakness in internal controls as a result of inadequate segregation of duties within account processes due to limited personnel and insufficient written policies and procedures for accounting, IT, and financial reporting and record keeping.

Industry Context

StockSavvy.ai notes that RF Acquisition Corp II operates as a Special Purpose Acquisition Company (SPAC). The current environment for SPACs is challenging, with increased scrutiny on deal structures and a higher rate of redemptions. The company's focus on deep technology in Asia aligns with emerging market trends, but the delays and going concern issues are common headwinds for SPACs struggling to find and close a suitable business combination within their mandated timelines.

Comparison to Industry Standards

• The average SPAC completion rate has been impacted by market conditions, with many facing extensions or liquidations.
• The significant redemption rates observed in this filing (e.g., $9.28 million in the second redemption) are higher than historical averages, indicating investor caution.
• The ongoing need for deadline extensions is a common theme among SPACs that have not yet identified or finalized a business combination, reflecting the difficulty in navigating current market and regulatory landscapes.

Corporate Governance

Related Party Transactions

• The Sponsor received 2,875,000 Founder Shares for $25,000 in operating costs.
• The Sponsor charges the Company $10,000 per month for office space, utilities, and administrative support.
• The Sponsor has provided advances for working capital purposes, with a balance of $396,600 due to Sponsor as of September 30, 2026.
• Nanyang Biologics Pte. Ltd. has made extension payments into the Trust Account on behalf of the Company.

Stakeholder Impact

• Shareholders face uncertainty regarding the completion of the business combination and the potential for liquidation.
• Redeeming shareholders have received a portion of their investment back, but non-redeeming shareholders remain exposed to the outcome of the business combination.
• Creditors may face risks if the company is unable to meet its obligations, although the Sponsor has agreed to indemnify the Trust Account against certain third-party claims.

Next Steps

• Complete the business combination with Nanyang Biologics Pte. Ltd. by November 15, 2026.
• Address material weaknesses in internal controls and strengthen disclosure procedures.
• Secure additional financing if necessary to complete the business combination or manage redemptions.
• If the business combination is not completed by the deadline, the company will cease operations, redeem public shares, and liquidate.

Key Dates

Recommendation

The company is in a precarious position with substantial doubt about its going concern status and a pending business combination that is subject to closing conditions. While a business combination has been approved, the ongoing extensions and financial uncertainties warrant a cautious 'hold' approach until the transaction is closer to completion and the financial health of the combined entity is clearer.

Keywords

SPAC, Business Combination, Nanyang Biologics, Trust Account, Shareholder Redemption, Going Concern, Extension, Deep Technology